rxstat › Classes › Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease (Gerd)

Drugs For Peptic Ulcer And Gastroesophageal Reflux Disease (Gerd): shortage status in Canada

8 of the 12 drugs for peptic ulcer and gastroesophageal reflux disease (gerd) rxstat tracks are currently in shortage in Canada, including 1 designated Tier 3 (most serious) by Health Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Famotidine (Acid Control) Widespread shortage 3 of 13 reported products affected · est. return Nov 30, 2026 Cimetidine Partial shortage 3 of 9 reported products affected Esomeprazole (Nexium -) Partial shortage 10 of 26 reported products affected · est. return Oct 10, 2027 Lansoprazole (Prevacid Fastab) Partial shortage 6 of 22 reported products affected · est. return Dec 29, 2026 Omeprazole (Losec) Partial shortage 10 of 22 reported products affected · est. return Sep 25, 2026 Pantoprazole (Tecta) Partial shortage 11 of 36 reported products affected · est. return Oct 31, 2026 Rabeprazole (Pariet, Enteric-Coated) Partial shortage 5 of 21 reported products affected · est. return Sep 18, 2026 Ranitidine (Zantac) Partial shortage 12 of 36 reported products affected Clarithromycin Amoxicillin Lansoprazole (Hp-Pac) No current shortage Dexlansoprazole (Dexilant) No current shortage Misoprostol No current shortage Sucralfate (Sulcrate) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.